Question

14. (23.20) Subjects with preexisting cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found...

14. (23.20) Subjects with preexisting cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9596 overweight or obese subjects with preexisting cardiovascular disease and/ or type 2 diabetes. The subjects were randomly assigned to subitramine (4887 subjects) or a placebo (4709 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 545 subjects in the subitramine group and 490 subjects in the placebo group. Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome? State hypotheses, find the test statistic and the P-value.

Test statistic (±0.001) z =

P-value (±0.001) =

Homework Answers

Answer #1

The statistical software output for this problem is:

From above output:

Test statistic = 1.178

P- value = 0.239

Know the answer?
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Not the answer you're looking for?
Ask your own homework help question
Similar Questions
(23.20) Subjects with preexisting cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to...
(23.20) Subjects with preexisting cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9802 overweight or obese subjects with preexisting cardiovascular disease and/ or type 2 diabetes. The subjects were randomly assigned to subitramine (4897 subjects) or a placebo (4905 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke,...
Subjects with pre‑existing cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be...
Subjects with pre‑existing cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9844 overweight or obese subjects with preexisting cardiovascular disease and/ or type 2 diabetes. The subjects were randomly assigned to subitramine (4899 subjects) or a placebo (4945 subjects) in a double‑blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation...
Subjects with pre-existing cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be...
Subjects with pre-existing cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9801 overweight or obese subjects with pre-existing cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to subitramine (4906 subjects) or a placebo (4895 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after...
Subjects with pre-existing cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be...
Subjects with pre-existing cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9801 overweight or obese subjects with pre-existing cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to subitramine (4906 subjects) or a placebo (4895 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after...